Supplements

September 2017 Br J Cardiol 2017;24(suppl 1):S2

Optimising the management of post ACS patients: Introduction

In this supplement we bring together four highly respected cardiology authors who provide an up-to-date analysis of the current management of the post-acute coronary syndrome...
Acute coronary syndrome in adults: scope of the problem in the UK

September 2017 Br J Cardiol 2017;24(suppl 1):S3–S9

Acute coronary syndrome in adults: scope of the problem in the UK

Click here to take a CPD test on this article Acute coronary syndrome (ACS) accounts for a substantial number of admissions to UK hospitals. As a...
Dual antiplatelet therapy following acute coronary syndromes: optimal regimens and duration of therapy

September 2017 Br J Cardiol 2017;24(suppl 1):S10–S15

Dual antiplatelet therapy following acute coronary syndromes: optimal regimens and duration of therapy

Click here to take a CPD test on this article Dual antiplatelet therapy (DAPT) post-acute coronary syndrome (ACS) is well established. Currently, three oral P2Y12 inhibitors...
The post-ACS patient: shared care to improve outcomes

September 2017 Br J Cardiol 2017;24(suppl 1):S16–S20

The post-ACS patient: shared care to improve outcomes

Click here to take a CPD test on this article The acute care of patients following myocardial infarction has progressed steadily over the past 29 years...
Introduction

November 2016 Br J Cardiol 2016;23(suppl 2):S1–S12

Introduction

Multiple clinical risk factors, electrocardiographic/echocardiographic features and biochemical markers are associated with an increased risk of atrial fibrillation (AF). AF poses a significant challenge from...
Direct current cardioversion and thromboprophylaxis in atrial fibrillation

November 2016 Br J Cardiol 2016;23(suppl 2):S1–S12

Direct current cardioversion and thromboprophylaxis in atrial fibrillation

Atrial fibrillation (AF) is the most common type of sustained cardiac arrhythmia, with an overall prevalence in the UK of 1.6% in women and 2.4%...
Introduction

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

Introduction

Heart failure is a leading cause of morbidity and mortality and presents many treatment challenges. Its prognosis is poor yet many patients do not receive...
Neurohumoral activation in heart failure and the implications for treatment

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

Neurohumoral activation in heart failure and the implications for treatment

The pathophysiology of heart failure is complex. This article describes the neurohumoral pathways that are active in chronic heart failure with left ventricular systolic dysfunction...
Clinical evidence to support the use of sacubitril/valsartan (LCZ696)

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

Clinical evidence to support the use of sacubitril/valsartan (LCZ696)

PARADIGM-HF was the first study to compare the long-term efficacy and safety of the angiotensin-receptor–neprilysin inhibitor (ARNI), sacubitril/valsartan (previously known as LCZ696), against standard care...
The use of sacubitril/valsartan (LCZ696) in clinical practice

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

The use of sacubitril/valsartan (LCZ696) in clinical practice

Professor John McMurray, the principal investigator in the PARADIGM-HF study, writes about his experience with sacubitril/valsartan (known as LCZ696 at the time of the study)...
A comment from primary care

June 2016 Br J Cardiol 2016;23(suppl 1):S1–S16

A comment from primary care

Much of the work in reducing the mortality and morbidity from heart failure will be carried out in primary care. Treatment of these patients with...
Pulmonary hypertension in UK clinical practice: an update

May 2015 Br J Cardiol 2015;22(suppl 1):S2–S15

Pulmonary hypertension in UK clinical practice: an update

Insights from the world of cardiology...
Unlocking the potential of NOACs

December 2014 Br J Cardiol 2014;21(suppl 2):S1–S7

Unlocking the potential of NOACs

Insights from the world of cardiology...
Rivaroxaban in non-valvular AF – UK experience in perspective

September 2014 Br J Cardiol 2014;21(suppl 1):S1–S11

Rivaroxaban in non-valvular AF – UK experience in perspective

Insights from the world of cardiology...
Rivaroxaban in non-valvular AF – French experience in perspective

September 2014 Br J Cardiol 2014;21(suppl 1):S1–S11

Rivaroxaban in non-valvular AF – French experience in perspective

Insights from the world of cardiology...
The French rivaroxaban experience: what we call progress is the exchange of one nuisance for another*

September 2014 Br J Cardiol 2014;21(suppl 1):S1–S11

The French rivaroxaban experience: what we call progress is the exchange of one nuisance for another*

Insights from the world of cardiology...
Novel oral anticoagulants in daily clinical practice – German experience with rivaroxaban

September 2014 Br J Cardiol 2014;21(suppl 1):S1–S11

Novel oral anticoagulants in daily clinical practice – German experience with rivaroxaban

Insights from the world of cardiology...

September 2014 Br J Cardiol 2014;21(suppl 1):S1–S11

European experiences reviewed

Insights from the world of cardiology...

December 2013 Br J Cardiol 2013;20(suppl 3):S1–S19

Introduction: Cardiovascular health and disease prevention in clinical practice

Insights from the world of cardiology...

December 2013 Br J Cardiol 2013;20(suppl 3):S1–S19

MyAction and the new cardiovascular outcomes strategy

Insights from the world of cardiology...